Modius Sleep News Today

Neurovalens, a global leader in non-invasive neuro-technology, has appointed Kate Willis to oversee the sales of the belfast firms prescribed medical devices in the US

Neurovalens announced today that it received FDA clearance for its Modius Stress device for treating anxiety and raised $2.65 million.

A health tech firm in Belfast has received medical device clearance in the US for a headset adapted to treat anxiety.

Biomimetic Innovations' injectable bone filler has been granted Breakthrough Designation by the FDA, giving a boost to its development.

A rise in the number of people being diagnosed with insomnia and the aging population are likely to increase demand for insomnia treatments.Wilmington, Delaware, United States, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global insomnia industry was worth US$ 3.8 billion in 2022. From 2023 to 2031, it is expected to increase at a CAGR of 6.0%, reaching US$ 6.4 billion. Various therapies have been explored for managing insomnia, offering non-pharmacological alternati

News and commentary from the psychiatry world

Neurovalens successfully secured 510(k) clearance from the FDA on October 27, 2023 for its Modius Sleep device with relation to treatment of insomnia and/or anxiety.   The clearance was...

The FDA granted 510(k) clearance to Neurovalens’ Modius Sleep noninvasive neurostimulator to treat chronic insomnia.

Health news and commentary from around the Web gathered by <em>MedPage Today</em> staff

Neurovalens is a former participant in the prestigious MedTech innovator competition. It is targeting a Series B funding round in 2024. Neurovalens, a…